Institute of Neurology, IRCCS San Raffaele, Rome, Italy.
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S54-7. doi: 10.1016/S1353-8020(09)70836-3.
The symptoms of Parkinson's disease (PD) can become increasingly difficult to control as the disease advances. L-dopa is the most efficacious therapy; however, with long-term therapy, motor and non-motor complications develop. There is now accumulating evidence that the progressive pathology of PD, the change in drug pharmaco-dynamics, and the pulsatile manner in which short-acting dopaminergic agents stimulate striatal dopamine receptors combine as key contributing factors to the priming of the basal ganglia for induction of motor complications. Dopamine receptor agonists have been extensively used as add-on therapy to L-dopa to treat motor complications. In this article we review the role of dopamine receptor agonists in the treatment of advanced parkinsonian patients.
帕金森病（PD）的症状随着疾病的进展会变得越来越难以控制。左旋多巴是最有效的治疗方法；然而，随着长期治疗，会出现运动和非运动并发症。现在有越来越多的证据表明，PD 的进行性病理改变、药物药代动力学的变化以及短效多巴胺能激动剂刺激纹状体多巴胺受体的脉冲方式，共同构成了基底神经节引发运动并发症的关键促成因素。多巴胺受体激动剂已被广泛用作左旋多巴的附加治疗方法，以治疗运动并发症。在本文中，我们综述了多巴胺受体激动剂在治疗晚期帕金森病患者中的作用。
